CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia
- 1 July 1991
- journal article
- clinical trial
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 40 (2) , 111-118
- https://doi.org/10.1016/0028-2243(91)90101-p
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- CV 205–502 Treatment of Hyperprolactinemia*Journal of Clinical Endocrinology & Metabolism, 1989
- Specific Effect of CV 205-502, a Potent Nonergot Dopamine Agonist, During a Combined Anterior Pituitary Function Test*Journal of Clinical Endocrinology & Metabolism, 1989
- In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205–502Brain Research, 1988
- Endocrine effects of CV 205-502, a new dopamine agonist, in hyperprolactinemic womenGynecological Endocrinology, 1988
- CV 205‐502: A NEW LONG‐ACTING DRUG FOR INHIBITION OF PROLACTIN HYPERSECRETIONClinical Endocrinology, 1987
- Drugs Five Years LaterAnnals of Internal Medicine, 1984
- HyperprolactinemiaThe American Journal of Medicine, 1983
- Prolactin and ReproductionFertility and Sterility, 1981
- A Broad Spectrum of Prolactin Suppression by Bromocriptine in Hyperprolactinemic Women: A Study of Serum Prolactin and Bromocriptine Levels after Acute and Chronic Administration ofBromocriptine*Journal of Clinical Endocrinology & Metabolism, 1980
- MANAGEMENT OF HYPERPROLACTINAEMIC AMENORRHOEABJOG: An International Journal of Obstetrics and Gynaecology, 1977